EGFR and neoplasm: These agents have demonstrated clinical activity in 8–20% of patients with non-small-cell lung cancer (NSCLC), especially in a subset of NSCLC patients whose tumours contain mutations involving the ATP binding pocket of the EGFR (Lynch et al, 2004; Paez et al, 2004).